Cargando…
Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
BACKGROUND: Liver cirrhotic patients with nonvalvular atrial fibrillation have been excluded from randomized clinical studies regarding oral anticoagulants for stroke prevention. Whether non–vitamin K antagonist oral anticoagulants (NOACs) are superior to warfarin for these patients remains unclear....
Autores principales: | Lee, Hsin‐Fu, Chan, Yi‐Hsin, Chang, Shang‐Hung, Tu, Hui‐Tzu, Chen, Shao‐Wei, Yeh, Yung‐Hsin, Wu, Lung‐Sheng, Kuo, Chang‐Fu, Kuo, Chi‐Tai, See, Lai‐Chu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474939/ https://www.ncbi.nlm.nih.gov/pubmed/30834802 http://dx.doi.org/10.1161/JAHA.118.011112 |
Ejemplares similares
-
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018) -
Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017) -
Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020) -
The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018) -
Young Male Patients with Atrial Fibrillation and CHA(2)DS(2)-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
por: Chan, Yi-Hsin, et al.
Publicado: (2016)